Key Takeaways Incyte's Q3 adjusted EPS of $2.26 beat estimates and more than doubled year over year.Revenues rose 20$1.37B, fueled by Jakafi and strong Opzelura demand in the U.S. market.New drugs Zynyz, Minjuvi, and Niktimvo posted robust sales, further boosting overall performance.Incyte Corporation (INCY) reported third-quarter 2025 adjusted earnings of $2.26 per share, which beat the Zacks Consensus Estimate of$1.66. The company had incurred adjusted earnings of $1.07 per share in the year-ago qua ...